ATE253554T1 - 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon - Google Patents

1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon

Info

Publication number
ATE253554T1
ATE253554T1 AT99928357T AT99928357T ATE253554T1 AT E253554 T1 ATE253554 T1 AT E253554T1 AT 99928357 T AT99928357 T AT 99928357T AT 99928357 T AT99928357 T AT 99928357T AT E253554 T1 ATE253554 T1 AT E253554T1
Authority
AT
Austria
Prior art keywords
1alpha
ene
analogues
vitamin
hydroxy
Prior art date
Application number
AT99928357T
Other languages
English (en)
Inventor
Charles W Bishop
Joyce C Knutson
Stephen Strugnell
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Application granted granted Critical
Publication of ATE253554T1 publication Critical patent/ATE253554T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99928357T 1998-05-29 1999-05-28 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon ATE253554T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/087,439 US5972917A (en) 1998-05-29 1998-05-29 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
PCT/US1999/012062 WO1999061418A2 (en) 1998-05-29 1999-05-28 1α-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE253554T1 true ATE253554T1 (de) 2003-11-15

Family

ID=22205199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928357T ATE253554T1 (de) 1998-05-29 1999-05-28 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon

Country Status (14)

Country Link
US (1) US5972917A (de)
EP (1) EP1082298B1 (de)
JP (1) JP2002516307A (de)
CN (1) CN1238341C (de)
AT (1) ATE253554T1 (de)
AU (1) AU754211B2 (de)
BR (1) BR9910672A (de)
CA (1) CA2333270A1 (de)
DE (1) DE69912598T2 (de)
DK (1) DK1082298T3 (de)
ES (1) ES2211107T3 (de)
IL (1) IL139353A (de)
PT (1) PT1082298E (de)
WO (1) WO1999061418A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
AU7363000A (en) * 1999-09-20 2001-04-24 Eli Lilly And Company Method for reducing the risk of cancer
EP2070911A2 (de) * 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilisiertes 1-alpha-Hydroxy-Vitamin D
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
US6465446B1 (en) * 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
KR20050044655A (ko) * 2001-12-03 2005-05-12 노바세아, 인크. 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물
CA2503801A1 (en) * 2001-12-26 2003-07-10 Chugai Seiyaku Kabushiki Kaisha 2-substituted vitamin d derivatives
KR20040095237A (ko) * 2002-03-29 2004-11-12 위스콘신 얼럼나이 리서어치 화운데이션 1α-히드록시-2-메틸렌-19-노르-호모프레그나칼시페롤의합성 방법
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
PL376148A1 (en) * 2002-10-23 2005-12-27 Leo Pharma A/S Vitamin d analogues, compositions comprising said analogues and their use
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
AU2004247109A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of cancer with active vitamin D compounds in combination with radiotherapeutic agents and treatments
PT103177A (pt) 2003-09-24 2005-03-31 Bioxell Spa 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006113990A2 (en) * 2005-04-25 2006-11-02 Cytochroma Inc. LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
RU2411038C2 (ru) * 2005-10-06 2011-02-10 Нестек С.А. Способ усиления эффективности вакцины и применение пробиотического штамма enterococcus faecium sf68 для усиления эффективности вакцины
US8318459B2 (en) 2011-02-17 2012-11-27 Purecircle Usa Glucosyl stevia composition
US9107436B2 (en) 2011-02-17 2015-08-18 Purecircle Sdn Bhd Glucosylated steviol glycoside as a flavor modifier
US9386797B2 (en) 2011-02-17 2016-07-12 Purecircle Sdn Bhd Glucosyl stevia composition
US8257948B1 (en) 2011-02-17 2012-09-04 Purecircle Usa Method of preparing alpha-glucosyl Stevia composition
US9392799B2 (en) 2011-02-17 2016-07-19 Purecircle Sdn Bhd Glucosyl stevia composition
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
KR20170096238A (ko) 2009-01-27 2017-08-23 베르그 엘엘씨 화학요법과 연관된 부작용을 경감시키기 위한 비타민 ｄ３ 및 이의 유사물
MX338746B (es) 2009-08-14 2016-04-29 Berg Llc Vitamina d3 y analogos de la misma para tratar alopecia.
US10696706B2 (en) 2010-03-12 2020-06-30 Purecircle Usa Inc. Methods of preparing steviol glycosides and uses of the same
WO2011112892A1 (en) 2010-03-12 2011-09-15 Purecircle Usa Inc. High-purity steviol glycosides
SI2552484T1 (sl) * 2010-03-29 2020-07-31 Opko Ireland Global Holdings, Ltd. Postopki in sestavki za znižanje ravni paratiroidnega hormona
BR112013014589B1 (pt) 2010-12-13 2019-04-02 Purecircle Usa Inc. Método para preparar uma composição de rebaudiosídeo d altamente solúvel
US9510611B2 (en) 2010-12-13 2016-12-06 Purecircle Sdn Bhd Stevia composition to improve sweetness and flavor profile
WO2012094550A2 (en) 2011-01-07 2012-07-12 The General Hospital Corporation Assays and methods of treatment relating to vitamin d insufficiency
US9052308B2 (en) 2011-01-07 2015-06-09 The General Hospital Corporation Assays and methods of treatment relating to vitamin D insufficiency
WO2014179737A2 (en) 2013-05-03 2014-11-06 The General Hospital Corporation Assays and methods of treatment relating to vitamin d insufficiency
US10362797B2 (en) 2011-02-10 2019-07-30 Purecircle Sdn Bhd Stevia composition
US9474296B2 (en) 2011-02-17 2016-10-25 Purecircle Sdn Bhd Glucosyl stevia composition
DE102011112532B4 (de) 2011-09-05 2019-03-21 Audi Ag Prüfeinrichtung und Verfahren zum Prüfen von Batteriezellen
CN103974628B (zh) 2012-05-22 2019-04-05 谱赛科有限责任公司 高纯度的甜菊醇糖苷
US9370527B2 (en) * 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
CA2913543C (en) 2013-05-29 2024-01-09 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
JP7572027B2 (ja) 2020-06-30 2024-10-23 国立研究開発法人農業・食品産業技術総合研究機構 セコステロイド構造を有する化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
JPS5626820A (en) * 1979-08-10 1981-03-16 Chugai Pharmaceut Co Ltd Immunosuppressing agent
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
DE3070985D1 (en) * 1979-10-23 1985-09-19 Teijin Ltd Process for the preparation of active-type vitamin d3 compounds and of the cholesta-5,7-diene precursors, and products so obtained
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4652405A (en) * 1981-08-28 1987-03-24 Hoffman-La Roche Inc. Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol
US4689180A (en) * 1984-01-30 1987-08-25 Wisconsin Alumni Research Foundation 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
DE3577552D1 (de) * 1984-11-27 1990-06-13 Chugai Pharmaceutical Co Ltd Vitamin d-derivate und verfahren zu deren herstellung.
US4749710A (en) * 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
KR0144358B1 (ko) * 1988-04-21 1998-07-15 피. 라이달 크리스텐슨 비타민 d 동족체
US5250523A (en) * 1988-04-29 1993-10-05 Wisconsin Alumni Research Foundation Side chain unsaturated 1α-hydroxyvitanim D homologs
ES2055019T3 (es) * 1988-12-12 1994-08-16 Duphar Int Res Metodo para la conversion fotoquimica de compuestos de taquisterol en compuestos de previtamina d y de compuestos de trans-vitamina d en compuestos de cis-vitamina d.
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
EP0494224B1 (de) * 1989-09-25 2000-05-10 University Of Utah Research Foundation Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
GB9007236D0 (en) * 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
ATE124394T1 (de) * 1990-04-27 1995-07-15 Duphar Int Res Verfahren zur photochemischen isomerisierung von organischen verbindungen unter dem einfluss eines photosensibilisators.
DE69327480T2 (de) * 1992-02-27 2002-11-21 Duphar International Research B.V., Weesp Verfahren zur Herstellung 9-Beta,10-Alpha-5,7-Dien-Steroiden
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9220439D0 (en) * 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5753638A (en) * 1992-10-07 1998-05-19 Hoffmann-La Roche Inc. Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
GB9223061D0 (en) * 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
US5449668A (en) * 1993-06-04 1995-09-12 Duphar International Research B.V. Vitamin D compounds and method of preparing these compounds
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
US5559107A (en) * 1994-10-20 1996-09-24 Gates; Stephen Regulation of immune response
DK0832063T3 (da) * 1995-06-14 2000-06-13 Schering Ag Vitamin D-derivater med substituenter på C-25, fremgangsmåde til deres fremstilling, mellemprodukter samt deres anvendelse
GB9524812D0 (en) * 1995-12-05 1996-02-07 Leo Pharm Prod Ltd Chemical compounds
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment

Also Published As

Publication number Publication date
PT1082298E (pt) 2004-03-31
CN1303368A (zh) 2001-07-11
EP1082298A2 (de) 2001-03-14
ES2211107T3 (es) 2004-07-01
IL139353A0 (en) 2001-11-25
DK1082298T3 (da) 2004-02-16
DE69912598D1 (de) 2003-12-11
EP1082298B1 (de) 2003-11-05
US5972917A (en) 1999-10-26
CA2333270A1 (en) 1999-12-02
DE69912598T2 (de) 2004-09-23
CN1238341C (zh) 2006-01-25
JP2002516307A (ja) 2002-06-04
WO1999061418A3 (en) 2000-03-23
BR9910672A (pt) 2001-01-30
WO1999061418A2 (en) 1999-12-02
AU754211B2 (en) 2002-11-07
AU4544599A (en) 1999-12-13
IL139353A (en) 2005-08-31

Similar Documents

Publication Publication Date Title
ATE253554T1 (de) 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon
ATE250566T1 (de) 24-hydroxy vitamin d, deren analogen und verwendungen
IL189629A0 (en) Compositions containing human ctla-4 antibodies
AU2003217055A1 (en) Protein for use in hypoxia related conditions
DE69926604D1 (de) Strahlungsundurchlässiges kollagenbiomaterial für implantierbare vorrichtungen
BR0214838A (pt) Composição para promoção de crescimento ósseo e manutenção da saúde óssea
ES270607Y (es) Implante de huesos, especialmente protesis para la articulacion de la cadera.
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
IL159300A0 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2003046695A3 (en) Methods and apparatus for automated interactive medical management
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
PL371464A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
ATE226947T1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
AU2003233735A8 (en) 24-sulfoximine vitamin d3 compounds
PT97337A (pt) Metodo para o tratamento de doencas neoplasticas com conjugados do acido difluoroglutamico com folatos e anti-folatos
MXPA03008039A (es) Polipeptidos de serpina humanos.
AU5870099A (en) Use of diltiazem for treating retinal pathologies
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
AU1506692A (en) Pharmaceutical compositions
ATE244230T1 (de) Dihydrobenzofluorenverbindungen, zwischenprodukte,zusammensetzungen und methode
NO20012169L (no) Forbindelser med veksthormonfrigjörende egenskaper

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082298

Country of ref document: EP

REN Ceased due to non-payment of the annual fee